Premium
[P3–210]: PLASMA SPHINGOLIPID RATIOS AND VERBAL MEMORY PERFORMANCE IN A CORONARY ARTERY DISEASE POPULATION AT RISK FOR VASCULAR COGNITIVE IMPAIRMENT (VCI) AND ALZHEIMER's DISEASE
Author(s) -
Dinoff Adam,
Saleem Mahwesh,
Herrmann Nathan,
Haughey Norman J.,
Oh Paul I.,
Mielke Michelle M.,
Lanctot Krista L.
Publication year - 2017
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2017.06.1423
Subject(s) - sphingolipid , sphingomyelin , ceramide , verbal memory , coronary artery disease , medicine , california verbal learning test , endocrinology , oncology , psychology , biology , cholesterol , cognition , biochemistry , neuroscience , apoptosis
established transcranialmagnetic stimulation technique that can assess the level of cholinergic activity in the brain. However, it is not yet known whether SAI is able to distinguish the low cholinergic activity in AD patients compared to unaffected controls and detect the improvement in cholinergic function in response to treatment with ChEI such as donepezil. The objective of this study was to assess whether SAI can be used as a biomarker for increased cholinergic activity, and hence measure potential improvements in response to treatments. Methods: 14 mild-to-moderate AD patients (age 73 +/7.1 years (mean +/-SD), 7 males, MMSE 23.3 +/3.3) on 10 mg donepezil once daily and 20 unaffected control subjects (age 67 +/7.3 years), 9males, meanMMSE 29.8 +/0.5) underwent 4 SAI sessions: 2 sessions per day w4 hours apart, 13.7 +/1.31 days apart. In the AD patient group, the first TMS session of the day was performed prior to the daily dose of donepezil, and the second 3 hours post dose. Results:A mixed analysis of variance revealed no significant difference between the SAI responses between AD patients pre or post donepezil dose and unaffected control subjects (p 1⁄4 0.275). There was also no significant intra-subject difference in the SAI responses preand postdonepezil dose in AD patients (p 1⁄4 0.870). Conclusions: SAI was not able to detect a significant difference in the brain cholinergic state between patients with mild-to-moderate AD and unaffected control subjects. In addition, repeat SAI did not detect intra-subject change in the brain cholinergic state before and 3 hours after administration of donepezil in patients with mild-tomoderate AD.